R1 Therapeutics Launches with $77.5M Series A to Advance CKD Treatment
Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...
Chronic Kidney Disease
Advertisement
WHO Grants INN to Anixa’s CAR-T Therapy for Ovarian Cancer
Dateline – November 17, 2025 | San Jose, California Anixa Biosciences, Inc. announced that the WHO’s International Non-proprietary Names...
AstraZeneca–Sun Pharma Join Forces to Expand Hyperkalaemia Treatment Access in India
Dateline – November 17, 2025 | Bengaluru, India In a significant development for India’s pharmaceutical ecosystem, AstraZeneca Pharma India...
Arch Biopartners Expands Phase II Kidney Injury Trial in Canada
TORONTO, November 5, 2025 — Arch Biopartners Inc. (TSXV: ARCH, OTCQB: ACHFF) announced that the Fraser Health Research Ethics...
Unicycive Therapeutics to Resubmit OLC NDA After FDA Type A Meeting
Los Altos, California, October 28, 2025 — Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for kidney disease,...
Advertisements
Roche AI Platform Gets CE Mark to Combat Kidney Disease
BASEL, Switzerland, Oct. 6, 2025 — Roche announced that it has received CE-mark approval for the AI-based Kidney Klinrisk...
Phraxis Marks First Commercial Use of EndoForce Anastomotic Connector
MINNEAPOLIS, August 29, 2025 — Phraxis announced the successful completion of the first-ever commercial case using its EndoForce Anastomotic...
Advertisement
